Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Editorial Policy
Trials
- Atogepant (AGN-241689)
- Erenumab (AMG 334)
- Galcanezumab (LY2951742)
- Fremanezumab (TEV-48125)
- Eptinezumab (ALD403)
- Rimegepant (BHV-3000)
- Ubrogepant (MK-1602)
Meeting Reports
- 12th European Headache Federation Congress
- 17th Biennial Migraine Trust International Symposium
- American Headache Society (AHS) 60th Annual Scientific Meeting
- 4th Congress of the European Academy of Neurology
- American Academy of Neurology (AAN) Congress
- 11th European Headache Federation Congress
- 18th Congress of the International Headache Society
- American Headache Society Annual Scientific Meeting
- 3rd Congress of the European Academy of Neurology
- American Academy of Neurology Annual Meeting
- Scottsdale Headache Symposium
- The European Headache and Migraine Trust International Congress (EHMTIC)
